Literature DB >> 8627263

Gag-Gag interactions in the C-terminal domain of human immunodeficiency virus type 1 p24 capsid antigen are essential for Gag particle assembly.

W H Zhang1, D J Hockley, M V Nermut, Y Morikawa, I M Jones.   

Abstract

Seven internal deletions within the p24 domain of the human immunodeficiency virus type 1 Gag precursor have been assessed for their effect on Gag particle formation following their expression using recombinant baculoviruses. In addition, each deleted molecule was assessed for its ability to bind soluble p24 antigen in vitro. The mutants fell into three different phenotypic groups: (i) three mutants that had no effect on either p24 binding or Gag particle assembly, (ii) three mutants that abolished both features and (iii) one mutant that bound p24 in vitro but failed to assemble particles. Mutations that abolished both in vitro p24 binding and particle assembly mapped to the C terminus of p24 confirming this region as critical for virion assembly. We suggest the division of virion assembly into at least two distinct phases and suggest a model in which the critical sequences mapped to date are combined with available structural information.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8627263     DOI: 10.1099/0022-1317-77-4-743

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  19 in total

1.  Entropic switch regulates myristate exposure in the HIV-1 matrix protein.

Authors:  Chun Tang; Erin Loeliger; Paz Luncsford; Isaac Kinde; Dorothy Beckett; Michael F Summers
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-29       Impact factor: 11.205

2.  Roles of matrix, p2, and N-terminal myristoylation in human immunodeficiency virus type 1 Gag assembly.

Authors:  Y Morikawa; D J Hockley; M V Nermut; I M Jones
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  Effects of Gag mutation and processing on retroviral dimeric RNA maturation.

Authors:  William Fu; Que Dang; Kunio Nagashima; Eric O Freed; Vinay K Pathak; Wei-Shau Hu
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

4.  Quantitative fluorescence resonance energy transfer microscopy analysis of the human immunodeficiency virus type 1 Gag-Gag interaction: relative contributions of the CA and NC domains and membrane binding.

Authors:  Ian B Hogue; Adam Hoppe; Akira Ono
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

5.  Detection of a trimeric human immunodeficiency virus type 1 Gag intermediate is dependent on sequences in the matrix protein, p17.

Authors:  Y Morikawa; W H Zhang; D J Hockley; M V Nermut; I M Jones
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

6.  Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites.

Authors:  K Wiegers; G Rutter; H Kottler; U Tessmer; H Hohenberg; H G Kräusslich
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

7.  Cryo-electron microscopy structure of yeast Ty retrotransposon virus-like particles.

Authors:  K J Palmer; W Tichelaar; N Myers; N R Burns; S J Butcher; A J Kingsman; S D Fuller; H R Saibil
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

8.  Association of human immunodeficiency virus type 1 gag with membrane does not require highly basic sequences in the nucleocapsid: use of a novel Gag multimerization assay.

Authors:  Akira Ono; Abdul A Waheed; Anjali Joshi; Eric O Freed
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

9.  HIV-1 Gag associates with specific uropod-directed microdomains in a manner dependent on its MA highly basic region.

Authors:  G Nicholas Llewellyn; Jonathan R Grover; Balaji Olety; Akira Ono
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

10.  Nucleocapsid promotes localization of HIV-1 gag to uropods that participate in virological synapses between T cells.

Authors:  G Nicholas Llewellyn; Ian B Hogue; Jonathan R Grover; Akira Ono
Journal:  PLoS Pathog       Date:  2010-10-28       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.